Open calls · Research grant · Medicine
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
National Institutes of Health · Oral Diseases and Disorders Research · PAR-28-022
Deadlines
- 25 Sep 2029 Deadline in 1046 days
Who can apply
- Where the work is done
- United States
- Who applies
- An organisation
Money
- Total budget
- $1.4M
- Expected awards
- 10
About the call
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Based on the proposed research, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). This is a re-issuance of PAR-23-284 . The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must reach a translational human endpoint within the project period of the grant.
Text from the funder (US federal government, public domain).
Conditions in full
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
We sort calls into fields, career stages and countries automatically. Always check the conditions on the funder’s page before you apply.
Discussion
Applying too? Looking for partners? Ask here.
